Non-Hodgkin lymphoma is expected to account for 80,550 new cases in the US. In Hodgkin lymphoma, painless cervical lymphadenopathy is the most common first sign, showing up in 70% of patients. This article connects how symptoms like fatigue and B symptoms vary by subtype and how staging and biomarkers help explain those differences in outcomes.
Key Takeaways
- Painless cervical lymphadenopathy is the most common presenting symptom in 70% of HL patients.
- B symptoms (fever, night sweats, weight loss >10%) occur in 40% of advanced HL and 20-30% early stage.
- 60-80% of NHL patients present with peripheral lymphadenopathy.
- PET-CT detects disease in 90-95% of HL staging.
- Excisional biopsy preferred for diagnosis, yielding 95% accuracy vs 70% core biopsy.
- Flow cytometry identifies B-cell clonality in 85-90% B-NHL.
- In 2023, an estimated 80,550 new cases of non-Hodgkin lymphoma (NHL) will be diagnosed in the US, with 20,140 deaths expected.
- The age-adjusted incidence rate for NHL in the US from 2016-2020 was 18.6 cases per 100,000 people per year.
- Globally, NHL incidence rates vary widely, with the highest age-standardized rates in Australia/New Zealand at 13.0 per 100,000 in men.
- 5-year OS for early favorable HL with ABVD x2 + INRT is 94-97%.
- DLBCL IPI 0-1: 5-year OS 90-95%, age >60 drops to 70%.
- HL stage IV 5-year survival 65-70% with modern therapy.
- Immunosuppression increases NHL risk 50-100 fold in transplant patients.
- HIV infection raises NHL risk by 50-200 times compared to general population.
- EBV is associated with 40-50% of HL cases in developing countries.
Most lymphomas start with swollen neck nodes or fatigue, but survival depends on early diagnosis and treatment.
Related reading
01 · Category
Clinical Presentation15 stats
01
Painless cervical lymphadenopathy is the most common presenting symptom in 70% of HL patients.
02
B symptoms (fever, night sweats, weight loss >10%) occur in 40% of advanced HL and 20-30% early stage.
03
60-80% of NHL patients present with peripheral lymphadenopathy.
04
Mediastinal mass found in 60% of nodular sclerosis HL cases.
05
Fatigue reported in 50-70% of lymphoma patients at diagnosis.
06
Bone marrow involvement in 10-20% of HL, 30-40% aggressive NHL at diagnosis.
07
Pruritus affects 10-30% of HL patients, often severe and generalized.
08
Abdominal pain or fullness in 20-30% of NHL due to splenomegaly or masses.
09
LDH elevation in 30-50% advanced NHL, prognostic marker.
10
Dyspnea from mediastinal involvement in 25% HL patients.
11
Cytopenias (anemia, thrombocytopenia) in 20-40% advanced lymphoma.
12
Superior vena cava syndrome rare, 2-5% mediastinal lymphomas.
13
Paraneoplastic autoimmune cytopenias in 5-10% indolent NHL.
14
Hypercalcemia in 5-15% aggressive lymphomas due to PTHrP.
15
Skin involvement in 20% cutaneous T-cell lymphomas like mycosis fungoides.
Interpretation
Clinical Presentation Interpretation
Lymphoma seems to have a twisted playbook, where the opening move is often a silent, swollen node, but the game quickly escalates into a full-body siege of night sweats, profound fatigue, and rogue symptoms from itching skin to crowded bones.
02 · Category
Diagnosis12 stats
01
PET-CT detects disease in 90-95% of HL staging.
02
Excisional biopsy preferred for diagnosis, yielding 95% accuracy vs 70% core biopsy.
03
Flow cytometry identifies B-cell clonality in 85-90% B-NHL.
04
Ann Arbor staging used: stage I 15%, II 40%, III 25%, IV 20% for HL.
05
Reed-Sternberg cells diagnostic in 95% classical HL biopsies.
06
Bone marrow biopsy positive in 5-15% early HL, 40% advanced NHL.
07
CD20 expression in 90% B-cell NHL, target for rituximab.
08
IPI score for DLBCL: high-risk >3 factors in 20%, poor prognosis.
09
MRI for spinal cord compression evaluation in 95% sensitivity.
10
FISH detects MYC translocation in 100% Burkitt lymphoma.
11
Lugano criteria for response: complete in 80% PET negative.
12
CSF analysis positive in 10-15% primary CNS lymphoma.
Interpretation
Diagnosis Interpretation
To confidently hunt lymphoma, we start with a scalpel's 95% certainty, track its stage with a PET scanner's keen eye, then arm ourselves with molecular tools like FISH to target its genetic weak spots, all to achieve that crucial 80% chance of complete response.
03 · Category
Epidemiology30 stats
01
In 2023, an estimated 80,550 new cases of non-Hodgkin lymphoma (NHL) will be diagnosed in the US, with 20,140 deaths expected.
02
The age-adjusted incidence rate for NHL in the US from 2016-2020 was 18.6 cases per 100,000 people per year.
03
Globally, NHL incidence rates vary widely, with the highest age-standardized rates in Australia/New Zealand at 13.0 per 100,000 in men.
04
Hodgkin lymphoma (HL) accounts for about 8% of all lymphomas, with approximately 8,570 new cases expected in the US in 2023.
05
The lifetime risk of developing NHL is 2.1% for men and 1.6% for women in the US.
06
In Europe, the crude incidence rate of NHL was 22.4 per 100,000 in 2020.
07
NHL prevalence in the US (2016-2020) was 82.1 per 100,000 among males and 62.5 per 100,000 among females.
08
HL incidence peaks in two age groups: 15-34 years and over 55 years, with a rate of 2.8 per 100,000 overall.
09
Worldwide, there were 544,000 new NHL cases in 2020, representing 2.7% of all cancers.
10
In the US, diffuse large B-cell lymphoma (DLBCL), the most common NHL subtype, comprises 30-40% of cases.
11
Age-adjusted HL incidence in the US (2016-2020) was 2.6 per 100,000 men and women.
12
NHL incidence has been stable or slightly declining in high-income countries since the 1990s.
13
In Asia, NHL incidence is lower at 5-7 per 100,000 compared to Western countries.
14
US NHL mortality rate (2016-2020) was 4.8 per 100,000.
15
HL is more common in males, with a male-to-female ratio of 1.3:1.
16
Globally, 259,000 NHL deaths occurred in 2020.
17
In the UK, annual NHL diagnoses are about 13,000.
18
Pediatric HL comprises 15% of all childhood lymphomas, with incidence 5.6 per million children.
19
NHL is the 7th most common cancer in the US.
20
Incidence of follicular lymphoma, a common indolent NHL, is 2-3 per 100,000.
21
HL incidence in developing countries is lower, around 1-2 per 100,000.
22
US 5-year relative survival for NHL improved from 50% in 1975 to 74% in 2020.
23
Mantle cell lymphoma incidence is 0.6 per 100,000, more common in older males.
24
In 2022, EU27 countries reported 65,000 NHL cases.
25
Burkitt lymphoma, aggressive NHL, has incidence <1 per 100,000 in non-endemic areas.
26
HL bimodal incidence: young adults 20-2.8/100k, elderly >55 4.5/100k.
27
NHL rates higher in Whites (19.7/100k) vs Blacks (15.3/100k) in US.
28
Global HL cases in 2020: 83,000 new, 22,000 deaths.
29
Marginal zone lymphoma incidence 1.5-2 per 100,000.
30
In Canada, NHL incidence 20.1/100k men, 14.2/100k women (2015-2019).
Interpretation
Epidemiology Interpretation
We see a landscape where lymphoma's global footprint is undeniable, yet its impact is a mosaic—from hopeful survival gains in the US to the sobering reality that, worldwide, over a quarter of a million lives are still lost to NHL each year.
More related reading
04 · Category
Prognosis23 stats
01
5-year OS for early favorable HL with ABVD x2 + INRT is 94-97%.
02
DLBCL IPI 0-1: 5-year OS 90-95%, age >60 drops to 70%.
03
HL stage IV 5-year survival 65-70% with modern therapy.
04
Indolent NHL like follicular 5-year OS 85-90%, but not cured.
05
Relapsed HL post-ASCT: median OS 3-5 years with BV/nivo.
06
Mantle cell lymphoma median OS 4-5 years, median PFS 1 year with intensive therapy.
07
Pediatric HL 5-year EFS 90-95% with OEPA-COPDAC.
08
Primary CNS lymphoma 5-year OS 30-40% with HD-MTX.
09
Burkitt lymphoma 5-year OS >90% adults/children with intensive chemo.
10
FLIPI high-risk follicular: 5-year PFS 25%, 10-year OS 50%.
11
Refractory DLBCL post-CAR-T median OS 12 months vs 4 months bispecifics improving.
12
Classical HL nodular sclerosis subtype 5-year OS 88%.
13
T-cell NHL median OS 2 years, worse than B-cell.
14
Elderly DLBCL >80 years 2-year OS 40-50% with R-miniCHOP.
15
Mixed cellularity HL 5-year OS 85%, better in developing countries.
16
Transformed indolent to aggressive NHL 5-year OS 30-50%.
17
NLPHL 10-year OS 90-95%, relapse indolent.
18
Double-hit lymphoma (MYC/BCL2) 2-year OS 25-30%.
19
HIV-NHL with ART + chemo 3-year OS 60-70%.
20
Post-transplant LPD 1-year OS 50%, 5-year 30%.
21
Peripheral T-cell lymphoma unspecified median OS 1.5 years.
22
Anaplastic large cell lymphoma ALK+ 5-year OS 80-90%, ALK- 40-50%.
23
Gastric MALT post-H pylori eradication CR 70-90%, long-term remission 80%.
Interpretation
Prognosis Interpretation
From these numbers emerges lymphoma's central, brutal truth: your chances hinge almost entirely on what type you have, where it is, and when you catch it, turning a single diagnosis into dozens of wildly different futures.
05 · Category
Risk Factors28 stats
01
Immunosuppression increases NHL risk 50-100 fold in transplant patients.
02
HIV infection raises NHL risk by 50-200 times compared to general population.
03
EBV is associated with 40-50% of HL cases in developing countries.
04
Autoimmune diseases like rheumatoid arthritis increase NHL risk by 2-4 fold.
05
Family history of lymphoma elevates NHL risk by 1.6-2.4 times.
06
Obesity (BMI >30) is linked to 20-30% increased risk of DLBCL.
07
Smoking increases risk of HL by 50% in current smokers under 45.
08
Organ transplant recipients have 5-30 fold higher NHL incidence.
09
Hepatitis C virus (HCV) infection associated with 2-3 fold NHL risk.
10
Pesticide exposure raises NHL risk by 40-80% in farmers.
11
Sjögren's syndrome increases marginal zone lymphoma risk 40-fold.
12
Celiac disease linked to 2.8-fold increased enteropathy-associated T-cell lymphoma risk.
13
Alcohol consumption inversely associated with HL risk, 20-40% lower in moderate drinkers.
14
Hair dyes (pre-1980) increased NHL risk by 1.5 times in frequent users.
15
EBV positivity in 70-80% of endemic Burkitt lymphoma cases.
16
Male gender increases HL risk, ratio 1.2-1.5 overall.
17
Methotrexate use in RA patients raises lymphoma risk 2-5 fold.
18
HTLV-1 infection causes 100% of adult T-cell leukemia/lymphoma cases in endemic areas.
19
Breast implants associated with rare anaplastic large cell lymphoma (ALCL) risk, incidence 1 in 3,000-30,000.
20
Helicobacter pylori infection precedes 90% of gastric MALT lymphomas.
21
Ionizing radiation exposure increases NHL risk by 1.2-2 fold.
22
Mononucleosis (EBV primary infection) raises HL risk 3-4 fold within 4 years.
23
Systemic lupus erythematosus (SLE) patients have 4-10 fold NHL risk.
24
Farming occupation linked to 1.4-fold NHL risk, especially DLBCL.
25
Chlamydia psittaci associated with 80% of ocular adnexal MALT lymphomas in some regions.
26
Night shift work increases NHL risk by 20-40% due to circadian disruption.
27
Common variable immunodeficiency (CVID) raises NHL risk 30-50 fold.
28
Persistent B-cell depletion after rituximab increases infection-related NHL risk.
Interpretation
Risk Factors Interpretation
It seems our body’s defense mechanisms are playing a high-stakes game of double agent, where a suppressed immune system, certain infections, and even our own misguided defenses can dramatically turn the tables, increasing lymphoma risk from a slight nudge to a staggering hundredfold invitation.
06 · Category
Treatment22 stats
01
CHOP-R regimen: cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2 max 2mg, prednisone 100mg x5 days.
02
ABVD for HL: doxorubicin 25mg/m2, bleomycin 10u/m2, vinblastine 6mg/m2, dacarbazine 375mg/m2, days 1+15 q28.
03
Rituximab 375mg/m2 weekly x4-8 with chemo improves DLBCL survival by 10-15%.
04
Radiation therapy dose 20-30 Gy for early stage HL, 5-year PFS 90%.
05
Autologous stem cell transplant (ASCT) cures 50% relapsed HL refractory cases.
06
Brentuximab vedotin (BV) 1.8mg/kg q3w post-ASCT improves PFS from 41% to 61% at 3 years in HL.
07
CAR-T therapy (axi-cel) ORR 82%, CR 54% in relapsed DLBCL.
08
Ibrutinib 560mg daily ORR 40% relapsed mantle cell lymphoma.
09
R-CHOP CR rate 75-80% in limited stage DLBCL.
10
Proton therapy reduces cardiac toxicity by 50% vs photon in mediastinal HL.
11
Lenalidomide 25mg days 1-21 q28 ORR 35% relapsed follicular lymphoma.
12
Polatuzumab vedotin + BR ORR 45%, CR 40% relapsed DLBCL.
13
Mini-CHOP dose reduction in elderly: 75% cyclophosphamide, doxorubicin, vincristine halved.
14
Tafasitamab + lenalidomide ORR 60%, CR 43% relapsed DLBCL ineligible ASCT.
15
Nivolumab 240mg q2w ORR 40% relapsed HL post-BV.
16
EPOCH-R: etoposide 50mg/m2 d1-4, prednisone 60mg/m2 d1-5, vincristine 0.4mg/m2 d1-4, cyclophosphamide 750mg/m2 d5, doxorubicin 10mg/m2 d1-4, rituximab 375mg/m2 d1.
17
Allogeneic SCT 5-year OS 40-50% high-risk relapsed NHL.
18
Venetoclax 400mg daily ORR 75% CLL/small lymphocytic lymphoma.
19
Involved site radiation therapy (ISRT) 30Gy standard for limited HL.
20
Acalabrutinib 100mg BID ORR 80% relapsed mantle cell.
21
GDP (gemcitabine 1000mg/m2 d1,8; dexamethasone 40mg d1-4; cisplatin 75mg/m2 d1) salvage ORR 60% DLBCL.
22
Bispecific Ab mosunetuzumab ORR 80%, CR 60% relapsed follicular.
Interpretation
Treatment Interpretation
While modern lymphoma care is a masterclass in calculated bombardment—from the precision strikes of proton therapy and bispecific antibodies to the cellular special forces of CAR-T—the enduring lesson is that success hinges on matching the right weapon to the right target at the right time.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Lymphoma Statistics. Gitnux. https://gitnux.org/lymphoma-statistics
MLA
Rachel Svensson. "Lymphoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/lymphoma-statistics.
Chicago
Rachel Svensson. 2026. "Lymphoma Statistics." Gitnux. https://gitnux.org/lymphoma-statistics.
Sources & references
14 datasets cited across this report · attribution is report-level